TriLink BioTechnologies社 December TriLink Messenger
|
この製品に関するご照会・お問合せはこちら
|
Research News |
|
Zone in with Zon for 2022 Blog Highlights
|
|
During the year 2022, more than 12,000 articles related to mRNA vaccines or mRNA therapeutics will have been added to the NIH PubMed database. This substantial volume of literature has provided many exciting topics to feature in this year’s blog posts. For our final post of 2022, we’re reflecting on the year to highlight major advancements in several broad areas of research covered in the blog.
 |
|
|
CRISPR-engineered universal T cells provide a novel approach to treating cancer
|
 Directed evolution of Cas9 broadens PAM sequence compatibility
|
|
Researchers at Great Ormond Street Hospital for Children and Great Ormond Street Institute of Child Health used TriLink-manufactured mRNA in a next-generation CAR T-cell therapy, providing complete remission from B-cell acute lymphoblastic leukemia in a phase 1 clinical trial.
|
Researchers at the Broad Institute of MIT and Harvard substitute TriLink’s N1-methyl-pseudouridine and CleanCap® AG in New England Biolabs HiScribe™ T7 High Yield RNA Synthesis Kit to validate a novel method for directed evolution of Cas9, which resulted in variants targeting previously inaccessible PAM sequences in the human genome.
|
UPCOMING EVENTS
mRNA-Based Therapeutic Summit Europe, Berlin
|
The highly anticipated mRNA-Based Therapeutics Summit Europe is returning to Berlin (January 25 - 27) as the most comprehensive, industry-leading meeting for mRNA experts in Europe.
Join 250+ pioneers from the likes of Moderna, Sanofi, BioNTech, Pantherna Therapeutics, and more as we explore the development of mRNA vaccines and therapies from research through to commercialisation and to patients in need.
Stay tuned for more info regarding our featured presentation at this conference.
|
|
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。
